Loading market dashboard
Global Partners LP
GLPEnergyNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced • Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist
Presentations will feature clinical results for ribupatide, a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight Additional data from Phase 2 obesity clinical trial of ribupatide oral demonstrating mean weight loss of up to 12.1% with no observed plateau and up to 38.6% of participants achieving at least 15% weight loss at 26 weeks; incidence of gastrointestinal adverse events was low, with v omiting reported in 11.4% and 7.5% of participants taking 25 mg and 50 mg ribupatide oral, respectively Phase 1 single ascending dose trial, the first ribupatide injection clinical data generated outside of China, demonstrated similar exposure, tolerability, and weight reduction in participants of Asian and non-Asian descent SHANGHAI and WALTHAM, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Hengrui Pharma (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, and Kailera Therapeutics, Inc. (Kailera), a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced clinical results for ribupatide (also known as HRS9531 or KAI-9531), a GLP-1/GIP receptor dual agonist being developed as a once-weekly injection and a once-daily oral pill for the treatment of obesity and overweight, presented at the 86th Scientific Sessions of the American Diabetes Association (ADA).
LLY's 2026 deal-making spree spans vaccines, oncology and neuroscience, aiming to diversify growth beyond GLP-1s amid rising obesity competition.
• Analysis of 20 muscle-preservation programs highlights a rapidly emerging category designed to enhance long-term obesity treatment outcomes
WW International (NASDAQ:WW) on Thursday said its Weight Watchers platform is now available through Eli Lilly Co.'s (NYSE:LLY) LillyDirect digital health care platform, expanding access to branded GLP-1 weight-loss medications alongside clinical and behavioral support services.
Eli Lilly's GLP-1 drugs Mounjaro and Zepbound are seeing massive demand. Like all drugs, Mounjaro and Zepbound have time-limited patent protections.
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Novo Nordisk's (NYSE:NVO) oral GLP-1 weight-loss drug Wegovy pill continues to outsell Eli Lilly's recently launched competing tablet, but weekly prescription growth is slowing as the market absorbs a new entrant, according to the latest tracking data. GLP-1, or glucagon-like peptide-1, refers to a class of drugs that mimic a gut hormone to suppress appetite and regulate blood sugar, and has become the most hotly contested space in global pharmaceuticals.
We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.
That means millions more Americans may get access to Lilly's new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.
Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma group. The key takeaway concerned the launch of Novo's oral semaglutide product, where the company confirmed that dose escalation patterns are not yet mirroring the trajectory seen with its injectable formulations.
Despite Wall Street skepticism, Novo Nordisk A/S is starting to catch up with Eli Lilly, the market leader in the GLP-1s market. This skepticism mainly reflects declining demand for Ozempic, as well as the weak performance of its long-acting insulin franchise. So, sales of Ozempic fell 12.6% quarter-on-quarter and 15% YoY to about DKK 27.83 billion in Q1.
Expanded GLP-1 options for members create a path to sustainable coverage of these important medications WOONSOCKET, R.I., May 28, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members— including the reintroduction of Zepbound® (tirzepatide) as a covered medication.
Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help with healthy weight loss, the first of its kind to be cleared by the FDA in 2025.
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the first dedicated phase III obesity study of the triple agonist drug, were broadly in line with the previously reported TRIUMPH-4 trial in obesity and knee osteoarthritis patients, which showed 28.7% weight loss at 68 weeks.
With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recommends Wegovy® pill for approval to reduce excess body weight and maintain long-term weight reduction.
Eli Lilly's investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers' first international generic GLP-1 offering, demonstrating the company's ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at $149 CAD/month, making.
Shares of Eli Lilly and Company NYSE: LLY, the world's most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%.
Deutsche Bank has maintained its 'hold' rating on Novo Nordisk (NYSE:NVO) with a price target of DKK290 after hosting the Danish drugmaker's head of research and development, Martin Lange. Analyst Emmanuel Papadakis said the key takeaway was that Novo is cautiously optimistic its cagrisema RD11 obesity study will yield a better result than the earlier RD4 trial, which disappointed markets when data was released.
I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings. NVO's pipeline, including high-dose Wegovy, zenagamtide, and UBT251, positions it closer to Eli Lilly than market sentiment suggests. Despite pricing and clinical setbacks, the company's stable revenue outlook and potential P/E re-rating support mid-teens annualized returns through 2030.
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Key Takeaways: On a year-over-year basis, 96.0% of the Alerian Midstream Energy Index (AMNA) by weighting have grown their dividends. MLPs largely drove sequential growth in payouts for 1Q26, while most corporations kept their dividends steady.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Vancouver, Canada, May 18, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the signing of a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. The agreement will fund a comprehensive preclinical study evaluating the metabolic efficacy of MEAI (CMND-100), both in combination with and as a maintenance therapy following tirzepatide treatment in diet-induced obese ("DIO") mice. The research will be conducted by Professor Joseph (Yossi) Tam and his team at the Obesity and Metabolism Laboratory at the Institute for Drug Research, School of Pharmacy, Hebrew University of Jerusalem.
Hims & Hers Health has returned to growth mode after volatility from the GLP-1 transition, yet trades near multi-year lows. The online health platform guided up 2026 revenues to $3B, exceeding consensus, and does not yet reflect the Eucalyptus acquisition. The company faces short-term margin pressure from branded GLP-1 drugs and international scaling, but the long-term target remains at least 20% EBITDA margins in 2030.
Losing muscle, as well as fat, is an unexpected downside of the popular drugs that isn't broadly discussed or immediately apparent.
J.P. Morgan upgraded Cheesecake Factory's stock, as weight-loss drugs and cautious consumers make the restaurant industry more anxious.
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Global Partners (GLP) possesses solid growth attributes, which could help it handily outperform the market.
- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today presented three-month good laboratory practice (GLP) toxicology data for VY1706, the Company's investigational tau silencing gene therapy for Alzheimer's disease (AD), in a late-breaking presentation at the American Society of Gene & Cell Therapy's (ASGCT) 2026 Annual Meeting in Boston, May 11-15, 2026.
Shares of telehealth provider Hims & Hers Health NYSE: HIMS sold off sharply following disappointing Q1 FY2026 financial results, with shares falling more than 12% in after-hours trading after the company reported on May 11.
With its best-in-breed GLP-1 drugs, Eli Lilly is beginning to cement itself as the dominant player in the massive GLP-1 market.
Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped around 15% before the opening bell after the company said changing dynamics in its GLP-1 weight-loss business had hurt margins and disrupted sales recognition during the quarter.
Shares in Novo Nordisk (NYSE:NVO) drew a cautious reception from Citi following first-quarter results that beat consensus expectations, with the bank raising its target price but retaining a neutral rating as concerns over portfolio price erosion and long-term obesity market competition outweigh a stronger-than-expected launch of the Wegovy pill. Citi lifted its target price to DKK290 in line with modest earnings upgrades of 2-3% for financial years 2027 to 2031, driven primarily by higher Wegovy pill estimates, while leaving its 2026 earnings per share forecast unchanged after cutting its sales estimate by 4% and operating income by 7% in constant currency.
CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27–30, 2026 in Barcelona, Spain.
Global Partners LP is upgraded from hold to buy as valuation and technicals turn favorable after a period of market-driven weakness. GLP's Q1 2026 revenue surged 16% YoY to $5.3B, with operating margin expanding to 2.0% amid successful acquisitions and rising oil prices. Despite high debt, GLP's liquidity and manageable maturity profile support its ability to sustain operations and dividends.
Global Partners NYSE: GLP reported a sharply higher first-quarter profit and cash flow, with management citing colder weather in the Northeast, stronger wholesale and commercial conditions, and improved fuel margins in its gasoline distribution and station operations business.
Global Partners LP Common Units (GLP) Q1 2026 Earnings Call Transcript
Wells Fargo just delivered a contrarian gut check to Nike (NYSE:NKE | NKE Price Prediction) stock bulls, downgrading the athletic wear giant to Equal Weight from Overweight and trimming its price target to $45 from $55.
� Analysis of 27 global triple-agonist programs highlights a rapidly expanding pipeline across major pharmaceutical companies and emerging biotech platforms.
Novo Nordisk (NYSE:NVO) oral version of its blockbuster weight-loss drug Wegovy is emerging as the central battleground for investors in the Danish pharmaceutical giant. And both UBS and Citi are highlighting the pill's trajectory as the defining question for the company's medium-term outlook following a strong set of first-quarter results and a London investor event.
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) today reported financial results for the first quarter ended March 31, 2026. CEO Commentary “Solid execution across all operating segments drove strong first‑quarter results for Global,” said Eric Slifka, the Partnership's President and Chief Executive Officer. “Performance this quarter reflects the advantages of our integrated platform in a dynamic market environment. “Our strategy is built to adapt to changing market conditions,.
SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA) announced it will serve as an independent program administrator in Eli Lilly and Company's Employer Connect program. Omada will offer its GLP‑1 Care Track, including clinical evaluation, prescribing, and ongoing medication management, to employers.
Eli Lilly's next-generation weight-loss drug, Retatrutide, could hit the shelves soon. Though the treatment has yet to attain FDA approval, demand is already so heavy that consumers are going to the black market to buy it.
Proprietary Semaglutide + Tirzepatide Dual-Peptide Formulation Now Available Exclusively Through the Tru2u.health Platform Lake Oswego, Portland--(Newsfile Corp. - May 6, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a pioneer in next-generation health and wellness solutions, today announced the official launch of GLP-Squared Injection, its groundbreaking dual-peptide injectable combining Semaglutide and Tirzepatide in a single, synergistic formulation. GLP-Squared is now exclusively available to members of the Company's flagship digital health platform, Tru2u.health.
Lilly's Foundayo is off to a strong start, drawing new prescribers and patients as broad pharmacy access and payer coverage fuel early oral obesity momentum.
Rejuvenate Muscle Health™ Adds Prominent GLP-1 Support Call-Out to New Packaging Set to Debut Later This Month Across North America; ECRM "Best Drink 2025" Validation; Promino™ NSF Certified for Sport® Extends Amino Platform into Performance Burlington, Ontario--(Newsfile Corp. - May 5, 2026) - Promino Nutritional Sciences, Inc. (CSE: MUSL) (OTCID: MUSLF) (FSE: 93X) ("Promino" or the "Company"), a performance nutrition company focused on clinically validated amino acid formulations, announces it is aligning with a growing shift toward muscle health support as Health Canada approves additional generic semaglutide products, expanding access to GLP-1 therapies used for weight loss and metabolic health. As GLP-1 medications become more widely used, attention is increasingly focused on maintaining lean muscle during weight loss - an important factor in supporting strength, mobility and overall health outcomes.
The hosts of Morning Brew Daily made a simple argument on a recent episode that the idea of the “Ozempic economy” should be replaced with the “Mounjaro economy” now that Eli Lilly is controlling 60% of the GLP-1 market.
Novo Nordisk's Wegovy pill has created another boom in the GLP-1 drug market. Eli Lilly recently introduced its Foundayo pill for weight loss, three months after the launch of its rival's drug.
New York City, NY, May 04, 2026 (GLOBE NEWSWIRE) -- DISCLAIMER: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription medications that require evaluation by a licensed clinician. If you purchase through links in this article, a commission may be earned at no additional cost to you.
The $63-billion GLP-1 agonist industry is forecast to triple in the coming decade, so it's no surprise that pharmaceuticals companies of all sizes are scrambling to get in on the action. For the time being, though, the market is still dominated by two names: Eli Lilly and Co. NYSE: LLY and Novo Nordisk A/S NYSE: NVO.
The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes The addition of Ozempic® pill will give Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for adults living with type 2 diabetes
Harris Teeter supports customers navigate weight management more affordably and comfortably with nutrition support, pharmacy expertise and fresh, quality foods. MATTHEWS, N.C.
GLP, STRA, FMX, SANM and SSRM have been added to the Zacks Rank #1 (Strong Buy) List on May 1, 2026.
STRA, GLP and FMX made it to the Zacks Rank #1 (Strong Buy) income stocks list on May 1, 2026.
STRA, GLP and ENVA made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 1, 2026.
Eli Lilly and Co (NYSE:LLY) reported stronger-than-expected first-quarter 2026 results on April 30, driven by surging demand for its diabetes and obesity treatments Mounjaro and Zepbound. Shares rose about 8% following the release.
More than 20,000 people have started taking Eli Lilly's GLP-1 pill Foundayo in its first few weeks on the market, Lilly CEO Dave Ricks told CNBC on Thursday.
